Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721)

Anticancer Research

Volumn 18, Issue 3 C, 1998, Pages 2203-2210

  Kurbacher, Christian M ^a   Mallmann, Peter K ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Amifostine; Chemotherapy; Cytoprotection; Dose intensity

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE; BLEOMYCIN; CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; MELPHALAN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; ONDANSETRON; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER; CARDIOTOXICITY; CELL PROTECTION; CONGESTIVE CARDIOMYOPATHY; FLUSHING; GRANULOCYTOPENIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HYPOMAGNESEMIA; HYPOTENSION; LEUKOPENIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MOUSE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031811052     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Davidson DE, Grenan MM and Sweeney TR: Biological characteristics of some improved radioprotectors. In Radiation sensitizers (Brady LW, ed). New York, NY, Masson pp 309-320, 1980.
2. Yuhas JM, Spellman JM and Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3: 211-216, 1980.
3. Phillips TL: Sensitizers and protectors in clinical oncology. Semin Oncol 8: 65-82, 1980.
4. Phillips TL, Yuhas JM and Wasserman TH: Differential protection against alkylating agent injury in tumors and normal tissues. In: Radioprotectors and anticarcinogens (Nygaard OF and Simic MG, eds). New York, NY, Academic, pp 735-748, 1983.
5. Van der Vigh WJF and Peters GJ: Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical Aspects. Semin Oncol 21 (Suppl 11): 2-7, 1994.
6. Capizzi RL, Scheffer BJ and Schein PS: Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72: 3495-3501.
7. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphoro-thioic acid. Cancer Res 40: 1519-1524; 1980.
8. Rasey JS, Spencer AM, Badger CC, et al: Specific protection of different normal tissues. Pharmacol Ther 39: 33-43, 1988.
9. Valeriote F and Tolen S: Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42: 4330-4331, 1982.
10. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, et al: The modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethlydithiocarbamate. Biochem Pharmacol 43: 1013-1019, 1992.
11. Treskes M, Boven E, Holwerda U, et al: Time-dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 52: 2257-2260, 1992.
12. Millar JL, McElwain TJ, Clutterbuck RD, et al: The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721). Am J Clin Oncol 5: 321-328, 1982.
13. Treskes M, Boven E, Van der Loosdrecht AA, et al: Effects of modulating agent WR-2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 30: 183-187, 1994.
14. Müller LJ, Moorer-Van Delft CM, Treskes M, et al: Properties of WR-2721 (Ethiofos) as a modulator of cisplatin-induced neurotoxicity studied at the ultrastructural level in the pond snail Lymnaea stagnalis. Int J Oncol 2: 701-710, 1993.
15. Milas L, Hunter N, Reid BO, et al: Protective effects of S-2-(3-aminopropylamino)-ethyl-phosphorothioic acid against damage of normal tissues and a fibrosarcoma in mice. Cancer Res 42: 1888-1897, 1982.
16. Nagy B, Dale PJ and Grdina DJ: Protection against cis-diarnminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)-amino] ethanethiol. Cancer Res 46: 1132-1135, 1986.
17. Nagy B and Grdina DJ: Protective effects of 2-[(aminopropyl)-amino] ethanethiol against bleomycin and nitrogen mustard induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 12: 1475-1478, 1986.
18. Green D, Wright A, Schein PS, et al: Protection from doxorubicin lethality in nude mice bearing MDA-MB-435 human breast cancer (abstr). Proc Amer Assoc Cancer Res 33: 490, 1992.
19. Dorr RT and Lagel K: Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro (abstr). Proc Am Soc Clin Oncol 13: 435, 1995.
20. Dorr RT: Cytoprotective agents for anthracyclines. Semin Oncol 23 (Suppl 8): 23-34, 1996.
21. DeBruijn EA, Dirix LY, Jorens, et al: Effects of amifostine on bleomycin-induced pulmonary toxicity in a murine model (abstr). Proc Amer Soc Clin Oncol 15: 545, 1996.
22. Shpall EJ, Stemmer SM, Hami L, et al: Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132-3137, 1994.
23. Douay L, Hu C, Giantarra MC, et al: Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 21 (Suppl 11): 16-20, 1994.
24. Douay L, Hu C, Giantarra MC, et al: Amifostine improves the antileukemic therapeutic index of mafosfamide (M): implications for bone marrow purging (abstr). Proc Amer Soc Clin Oncol 14: 74, 1995.
25. List AF, Heaton R, Glinsmann-Gibson B, et al: Amifostine protects primitive human hematopoietic progenitors against cytotoxicity from diverse antineoplastics (abstr). Poe Amer Soc Clin Oncol 15: 532, 1996.
26. Cagnoni P PJ, Jones RB, Bearman SC, et al: Use of amifostine in bone marrow purging. Semin Oncol 23 (Suppl 8): 44-48, 1996.
27. List AF, Heaton R, Glinsmann-Gibson B, et al: Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23 (Suppl 8): 58-63, 1996.
28. List AF, Heaton B, Glinsmann-Gibson, et al: Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc Amer Soc Clin Oncol 15: 449, 1996.
29. Treskes M and Van der Vijgh WJF: WR-2721 as a modulator of cisplatin- and carboplatin-induced side-effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 33: 93-106, 1993.
30. Glover DJ, Glick JH, Weiler C, et al: WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 4: 584-588, 1986.
31. Glover DJ, Glick JH, Weiler C, et al: Phase VII tnals of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 12: 1509-1512, 1986.
32. Glover DJ, Glick JH, Weiler C, et al: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5: 574-578, 1987.
33. Balch CM, Houghton AN and Peters LJ: Cutaneous melanoma. In: Cancer: principles and practice of oncology, 4th ed (DeVita VT Jr, Hellman S and Rosenberg SA, eds.) Lippincott, Philadelphia (PA), 1993, pp 1612-1661.
34. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neurotoxicity, risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192-2195, 1988.
35. Poplin EA, LoRusso P, Lokich JJ, et al: Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415-419, 1994.
36. Riggs CE Jr: Antitumor antibiotics and related compounds. In: The chemotherapy source book, 2nd ed (Perry MC, ed). Williams & Wilkins, Baltimore, 1996, pp 345-385.
37. Planting AST, Vermorken JB, Catimel G, et al: Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer (abstr). Int J Cancer Res Treat 18 (Suppl 2): 93, 1995.
38. Perry DJ, Krasnow SH, Reilly JG, et al: Phase II study of cisplatin and etoposide with WR-2721 (ETHYOL) for advanced non-small cell lung cancer (abstr). Proc Am Soc Clin Oncol 13: 359, 1994.
39. Schiller JH, Storer B, Wittenkeller et al: Amifostine, cisplatin, and vinblastine in non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 14: 1913-1921, 1996.
40. Mehta M, Larson MM, Pharo L, et al: Phase II clinical trial of amifostine, cisplatin, vinblastin (ACV) and radiation therapy (RT) for unresectable stage III non-small cell lung cancer (NSCLC) (abstr). Proc Am Soc Clin Oncol 14: 373, 1995.
41. Betticher DC, Anderson H, Ranson M, et al: Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Br J Cancer 72: 1551-1555, 1995.
42. Jahanzeb M and Ihde DC: Chemotherapy of lung cancer. In: The chemotherapy source book, 2nd ed (Perry MC, ed). Williams and Wilkins, Baltimore, 1996, pp 1103-1123.
43. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-indueed toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112, 1996.
44. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer. An overview of randomised clinical trials. Br Med J 303: 884-893, 1987.
45. Canistra SA: Cancer of the ovary. New Engl J Med 329: 1550-1559, 1993.
46. Kataoka Y, Perrin J, Hunter N, et al: Antimutagenic effects of amifostine: clinical implications. Semin Oncol 23 (Suppl 8): 53-57, 1996.
47. Pui CH, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321: 136-142, 1989.
48. Robinson LL and Mertens A: Second tumors after treatment of childhood malignancies. Hematol Oncol Clin North Am 7: 401-415, 1993.
49. Klein CE: Gonadal complications and teratogenicity of cancer therapy. In: The chemotherapy source book, 2nd ed (Perry MC, ed). Williams and Wilkins, Baltimore, 1996, pp 813-832.
50. Heyn R, Khan F, Ensign LG, et al: Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol 23: 99-106, 1989.
51. Pui CH, Ribeiro RC, Hancock, et al: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute Iymphoblastic leukemia. N Engl J Med 325: 1682-1687, 1991.
52. Tucker MA, Meadows AT, Boice JD Jr, et al: Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst. 78: 459-464, 1987.
53. Fulda S, Oster W and Berthold F: Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anti-Cancer Drugs 8: 34-41, 1997.
54. Fichtner I, Lemm M, Becker M, et al: Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anti-Cancer Drugs 8: 174-181, 1997.
55. Adamson PC, Balsi FM, Belasco JE, et al: A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 55: 4069-4072, 1995.
56. Borsi JD, Csaki C, Ferenez T, et al: Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematologic toxicity of high dose carboplatin. Anti-Cancer Drugs 7: 121-126, 1996.
57. Cairo MS, Shen WPV, Miser J, et al: A randomized trial of two doses of G-CSF (5.0 vs 10 mg/kg/d) following ifosfamide, carboplatin, and etoposide (ICE) chemotherapy in children with recurrent solid tumors: significant clinical activity but no improvement in hematopoietic recovery with increased dose of G-CSF (abstr). Proc Am Soc Clin Oncol 14: 255, 1995.
58. Runowicz CD, Smith HO and Goldbert G: Multimodality therapy in locally advanced cervical carcinoma. Curr Opin Obstet Gynecol 5: 92-98, 1993.
59. O'Connell M, Martenson J, Wienand H, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502-507, 1994.
60. Wadler S, Haynes H, Rubin JS, et al: A pilot clinical trial of cisplatin, radiation therapy and the chemoprotective agent. WR2721, against carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study: J Clin Oncol 11: 1511-1516, 1993.
61. Wadler S, Goldberg G, Fields A, et al: The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix: Semin Oncol 23 (Suppl 8): 64-68, 1996.
62. Gianni L, Muzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
63. DiPaola R, Rodriguez R, Recio A., et al: A phase I study of amifostine and paclitaxel in patients with advanced malignancies (abstr): Proc Am Soc Clin Oncol 15: 488, 1996.
64. Thigpen JT, Vance RB and Khansur T: Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71: 1559-1564, 1993.
65. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
66. Ozols RF: Carboplatin and paclitaxel in ovarian cancer. Semin. Oncol 22 (Suppl 6): 78-83, 1995.
67. Paine GD, Taylor CW, Lopez MHA, et al: Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol 23 (Suppl 8): 35-39, 1996.
68. Mansi JL, Berger U, Eastin D, et al: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295: 1093-1093, 1987.
69. Cote RJ, Rosen PR, Lesse ML, et al: Prediction of early relapse in patients with operable breast cancer by detection of occult metastases. J Clin Oncol 9: 1749-1756, 1991.
70. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84: 380-383, 1994.
71. Brenner M, Mirro J Jr, Hurwitz C, et al: Gene-marking to trace the origin of relapse after autologous bone-marrow transplantation. Lancet 341: 85-86, 1993.
72. Shpall EJ, Jones RB, Bast RC Jr, et al: 4-Hydroperoxy-cyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9: 85-93, 1991.
73. Norton L and Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70: 163-169, 1986.
74. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. J Am Med Assoc 273: 542-547, 1995.
75. Norton L: The Norton-Simon hypothesis. In: The chemotherapy source book, 2nd ed (Perry MC, ed.). Williams and Wilkins, Baltimore, 1996, pp 43-61.
76. Loeffler TM, Freund W, Lipke J, et al: Schedule and dose intensified paclitaxel (T) as weekly one hour infusion: evidence for an improved toxicity profile and response activity in pretreated solid tumors (abstr). Proc Am Soc Clin Oncol 14: 470, 1995.
77. Kurbacher CM, Bruckner HW, Cree IA, et al: Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 3: 1527-1533, 1997.
78. Schuchter LM: Guidelines for the administration of amifostine. Semin Oncol 23 (Suppl 8): 40-43, 1996.
79. Rieth A, Schuth J and Kudielka RA: Cytoprotection in chemo- and radiotherapy with amifostine (ethyol): a new strategy in oncology. Onkologie 19: 315-320, 1996.
80. Schuchter LM and Glick JH: The current status of WR-2721 (amifostine): a chemotherapy and radiation therapy protector. Biol Ther Cancer Updates 3: 1-10, 1993.
81. Stemmer SM, Shpall EJ, Jones RB, et al: Amifostine (WR-2721) shortens the engraftment time of 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow in lymphoma patients receiving high-dose chemotherapy (hdc) with autologous bone marrow support (abstr). Blood 10 (Suppl 1): 70a, 1992.
82. Budd GT, Bukowski RM, Murthy S, et al: Randomized trial of carboplatin (CBDCA) vs. CBDCA+amifostine (AMI) in advanced malignancy (abstr.). Proc Am Soc Clin Oncol 33: 415-419,